|
1
|
Visci G, Rizzello E, Zunarelli C, Violante
FS and Boffetta P: Relationship between exposure to ionizing
radiation and mesothelioma risk: A systematic review of the
scientific literature and meta-analysis. Cancer Med. 11:778–789.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tandon RT, Jimenez-Cortez Y, Taub R and
Borczuk AC: Immunohistochemistry in peritoneal mesothelioma: A
single-center experience of 244 cases. Arch Pathol Lab Med.
142:236–242. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Calabrò L, Rossi G, Morra A, Rosati C,
Cutaia O, Daffinà MG, Altomonte M, Di Giacomo AM, Casula M, Fazio
C, et al: Tremelimumab plus durvalumab retreatment and 4-year
outcomes in patients with mesothelioma: A follow-up of the open
label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir
Med. 9:969–976. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Venur VA, Santagata S, Galanis E and
Brastianos PK: New molecular targets in meningiomas: The present
and the future. Curr Opin Neurol. 31:740–746. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Blee TK, Gray NK and Brook M: Modulation
of the cytoplasmic functions of mammalian post-transcriptional
regulatory proteins by methylation and acetylation: A key layer of
regulation waiting to be uncovered? Biochem Soc Trans.
43:1285–1295. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Popat S, Baas P, Faivre-Finn C, Girard N,
Nicholson AG, Nowak AK, Opitz I, Scherpereel A and Reck M:
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 33:129–142.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Galateau-Salle F, Churg A, Roggli V and
Travis WD: World Health Organization Committee for Tumors of the
Pleura. The 2015 world health organization classification of tumors
of the pleura: Advances since the 2004 Classification. J Thorac
Oncol. 11:142–154. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chapel DB, Husain AN, Krausz T and
McGregor SM: PAX8 expression in a subset of malignant peritoneal
mesotheliomas and benign mesothelium has diagnostic implications in
the differential diagnosis of ovarian serous carcinoma. Am J Surg
Pathol. 41:1675–1682. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lemen RA: Mesothelioma from asbestos
exposures: Epidemiologic patterns and impact in the United States.
J Toxicol Environ Health B Crit Rev. 19:250–265. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Tsao AS, Wistuba I, Roth JA and Kindler
HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Singhi AD, Krasinskas AM, Choudry HA,
Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N,
Seethala RR and Dacic S: The prognostic significance of BAP1, NF2,
and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol.
29:14–24. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hwang HC, Sheffield BS, Rodriguez S,
Thompson K, Tse CH, Gown AM and Churg A: Utility of BAP1
immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of
malignant mesothelioma in effusion cytology specimens. Am J Surg
Pathol. 40:120–126. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hiroshima K, Wu D, Hamakawa S, Tsuruoka S,
Ozaki D, Orikasa H, Hasegawa M, Koh E, Sekine Y, Yonemori Y, et al:
HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant
mesothelioma with effusion. Diagn Cytopathol. 49:622–632.
2021.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Ordóñez NG: Value of PAX8, PAX2,
claudin-4, and h-caldesmon immunostaining in distinguishing
peritoneal epithelioid mesotheliomas from serous carcinomas. Mod
Pathol. 26:553–562. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lim CB, Prêle CM, Cheah HM, Cheng YY,
Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ and Mutsaers SE:
Mutational analysis of hedgehog signaling pathway genes in human
malignant mesothelioma. PLoS One. 8(e66685)2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cigognetti M, Lonardi S, Fisogni S,
Balzarini P, Pellegrini V, Tironi A, Bercich L, Bugatti M, Rossi G,
Murer B, et al: BAP1 (BRCA1-associated protein 1) is a highly
specific marker for differentiating mesothelioma from reactive
mesothelial proliferations. Mod Pathol. 28:1043–1057.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang X, Yang L, Chen W and Kong M:
Identification of potential hub genes and therapeutic drugs in
malignant pleural mesothelioma by integrated bioinformatics
analysis. Oncol Res Treat. 43:656–671. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Righi L, Duregon E, Vatrano S, Izzo S,
Giorcelli J, Rondón-Lagos M, Ascoli V, Ruffini E, Ventura L,
Volante M, et al: BRCA1-associated protein 1 (BAP1)
immunohistochemical expression as a diagnostic tool in malignant
pleural mesothelioma classification: A large retrospective study. J
Thorac Oncol. 11:2006–2017. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhao X and Wu X: Polycomb-group proteins
in the initiation and progression of cancer. J Genet Genomics.
48:433–443. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mohamed IZB, Idle M, Bates T and Yahya S:
Tongue: The unusual site in malignant pleural mesothelioma. BMJ
Case Rep. 14(e241166)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Inoue N, Takumi K, Sone D, Shirakawa A,
Kawamura T and Uno K: Malignant peritoneal mesothelioma with latent
tuberculosis infection. Intern Med. 60:3409–3412. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Pazyar N, Yaghoobi R, Rafiee E, Mehrabian
A and Feily A: Skin wound healing and phytomedicine: A review. Skin
Pharmacol Physiol. 27:303–310. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Mazurek JM, Syamlal G, Wood JM, Hendricks
SA and Weston A: Malignant mesothelioma mortality-United States,
1999-2015. MMWR Morb Mortal Wkly Rep. 66:214–218. 2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Meyerhoff RR, Yang CF, Speicher PJ, Gulack
BC, Hartwig MG, D'Amico TA, Harpole DH and Berry MF: Impact of
mesothelioma histologic subtype on outcomes in the surveillance,
epidemiology, and end results database. J Surg Res. 196:23–32.
2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Brich S, Bozzi F, Perone F, Tamborini E,
Cabras AD, Deraco M, Stacchiotti S, Dagrada GP and Pilotti S:
Fluorescence in situ hybridization (FISH) provides estimates
of minute and interstitial BAP1, CDKN2A and
NF2 gene deletions in peritoneal mesothelioma. Mod Pathol.
33:217–227. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Henderson DW, Reid G, Kao SC, van Zandwijk
N and Klebe S: Challenges and controversies in the diagnosis of
mesothelioma: Part 1. Cytology-only diagnosis, biopsies,
immunohistochemistry, discrimination between mesothelioma and
reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol.
66:847–853. 2013.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Chapel DB, Dubuc AM, Hornick JL and Sholl
LM: Correlation of methylthioadenosine phosphorylase (MTAP) protein
expression with MTAP and CDKN2A copy number in malignant pleural
mesothelioma. Histopathology. 78:1032–1042. 2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Frau M, Feo F and Pascale RM: Pleiotropic
effects of methionine adenosyltransferases deregulation as
determinants of liver cancer progression and prognosis. J Hepatol.
59:830–841. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Husain AN, Colby TV, Ordóñez NG, Allen TC,
Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S,
et al: Guidelines for pathologic diagnosis of malignant
mesothelioma 2017 update of the consensus statement from the
international mesothelioma interest group. Arch Pathol Lab Med.
142:89–108. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kukuyan AM, Sementino E, Kadariya Y,
Menges CW, Cheung M, Tan Y, Cai KQ, Slifker MJ, Peri S,
Klein-Szanto AJ, et al: Bap1 inactivation of cooperates with losses
of Nf2 and Cdkn2a to drive the development of pleural
malignant mesothelioma in conditional mouse models. Cancer Res.
79:4113–4123. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Seastedt KP, Pruett N and Hoang CD: Mouse
models for mesothelioma drug discovery and development. Expert Opin
Drug Discov. 16:697–708. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Henderson DW, Reid G, Kao SC, van Zandwijk
N and Klebe S: Challenges and controversies in the diagnosis of
malignant mesothelioma: Part 2. Malignant mesothelioma subtypes,
pleural synovial sarcoma, molecular and prognostic aspects of
mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol.
66:854–861. 2013.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Musk AW, Olsen N, Alfonso H, Reid A, Mina
R, Franklin P, Sleith J, Hammond N, Threlfall T, Shilkin KB and de
Klerk NH: Predicting survival in malignant mesothelioma. Eur Respir
J. 38:1420–1424. 2011.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Andrici J, Jung J, Sheen A, D'Urso L,
Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A,
et al: Loss of BAP1 expression is very rare in peritoneal and
gynecologic serous adenocarcinomas and can be useful in the
differential diagnosis with abdominal mesothelioma. Hum Pathol.
51:9–15. 2016.
|
|
35
|
Kapur P, Christie A, Raman JD, Then MT,
Nuhn P, Buchner A, Bastian P, Seitz C, Shariat SF, Bensalah K, et
al: BAP1 immunohistochemistry predicts outcomes in a
multi-institutional cohort with clear cell renal cell carcinoma. J
Urol. 191:603–610. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Cottone L, Eden N, Usher I, Lombard P, Ye
H, Ligammari L, Lindsay D, Brandner S, Pižem J, Pillay N, et al:
Frequent alterations in p16/CDKN2A identified by
immunohistochemistry and FISH in chordoma. J Pathol Clin Res.
6:113–123. 2020.PubMed/NCBI View
Article : Google Scholar
|
